Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immtech Pharmaceuticals has announced that China's State Food and Drug Administration has granted fast track status for its Phase III clinical trial of pafuramidine, an oral drug candidate for the treatment of pneumocystis pneumonia.
Subscribe to our email newsletter
Pafuramidine is among the first drugs to be considered for fast track status under new and more stringent State Food and Drug Administration (SFDA) rules recently introduced in China.
Eric Sorkin, chairman and CEO of Immtech said: “This is a significant milestone for Immtech to work in China to accelerate the approval and availability of Pafuramidine as a treatment for pneumocystis pneumonia (PCP). As the most populous nation in the world, China is well positioned to support and benefit from important efforts to combat PCP and other devastating infectious diseases.”